Cresco Labs Inc.

CL

CA22587M1068

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 10:08:08 2024-04-26 am EDT			5-day change	1st Jan Change
2.7 ^CAD	+1.50%		-1.82%	+50.84%

Apr. 15	Jushi Holdings Inc. Brief: Appointed Todd West as Chief Operating Officer, Effective April 12, 2024; Most Recent Role Was As Executive Vice President of Operations at Cresco Labs Inc	MT
Mar. 13	Cresco Labs Swings to Profit in Q4, Revenue Drops; Up 10.4%	MT

Cresco Labs Inc. Provides Earnings Guidance for the Year 2021

May 27, 2021 at 07:30 am EDT

Cresco Labs Inc. provided earnings guidance for the year 2021. For the year, the company expects annualized revenue run-rate of more than $1 billion by the end of 2021.

Latest news about Cresco Labs Inc.

Jushi Holdings Inc. Brief: Appointed Todd West as Chief Operating Officer, Effective April 12, 2024; Most Recent Role Was As Executive Vice President of Operations at Cresco Labs Inc	Apr. 15	MT
Cresco Labs Swings to Profit in Q4, Revenue Drops; Up 10.4%	Mar. 13	MT
Cresco Labs Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Cresco Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Cresco Labs Inc. Provides Revenue Guidance for the First Quarter of 2024	Mar. 13	CI
Transcript : Cresco Labs Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Cresco Labs Swings to Profit in Q4, Revenue Drops	Mar. 13	MT
Cresco Labs Brief: Fourth quarter revenue of US$188 million; net income of $5 million.	Mar. 13	MT
Cresco Labs Continues Retail Expansion in Pennsylvania with New Gettysburg Store	Feb. 23	CI
Cresco Labs Inc. Promotes Greg Butler to the Position of President	Feb. 01	CI
Cresco Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
Transcript : Cresco Labs Inc., Q3 2023 Earnings Call, Nov 15, 2023	Nov. 15
Earnings Flash (CL) CRESCO LABS Posts Q3 Revenue $190.6M	Nov. 15	MT
Cresco Labs Unlocking US$32 Million in Non-Dilutive Capital	23-10-19	MT
The Mint Cannabis completed the acquisition of Encanto Green Cross Dispensary, LLC from Cresco Labs Inc. (CNSX:CL) for $6.5 million.	23-10-18	CI
Cresco Labs Inc. Launches Good News Brand in Pennsylvania with New Sweet Troches	23-10-09	CI
Cresco Labs Inc. Expands Sunnyside in Central Pennsylvania with New Store in Altoona	23-10-05	CI
SAFER Banking Act Passes Banking Committee, Sent to the Floor, Notes Wedbush	23-09-27	MT
Cresco Labs Launches New Brands in Florida; Down 6.2%	23-09-21	MT
Cresco Labs Launches New Brands in Florida	23-09-21	MT
Cresco Labs Expands Florida Brand Portfolio with Launch of Floracal and Cresco Live Rosin and Flower Products	23-09-21	CI
Piper Sandler on US Opportunities For Cannabis Companies	23-09-18	MT
Cresco Labs Inc. Opens 33Rd Florida Sunnyside in Jacksonville, 70Th Store Nationwide	23-09-12	CI
Piper Sandler On Cresco Labs; Citing "Impressive Margin Momentum"	23-08-16	MT
Cresco Labs Inc. Provides Revenue Guidance for the Second Half of 2023	23-08-16	CI

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labsâ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindyâs. Its portfolio consists of over 400 products. The Company's products are sold in over 1,600 dispensaries across the country. Its Cresco offers consistent strains, available in a variety of product forms at dispensaries and retail locations nationwide. Its High Supply lab-tested; and available in vape carts, vape pens, flower, popcorn, shake, shorties and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Its Mindyâs offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cresco Labs Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.942 USD

Average target price

4.363 USD

Spread / Average Target

+124.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRESCO LABS INC.	+50.84%	675M
ELI LILLY AND COMPANY	+26.02%	653B
NOVO NORDISK A/S	+26.67%	556B
JOHNSON & JOHNSON	-6.66%	354B
MERCK & CO., INC.	+20.31%	331B
ABBVIE INC.	+3.80%	296B
ASTRAZENECA PLC	+12.85%	233B
NOVARTIS AG	+5.57%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.23%	144B

Other Pharmaceuticals

Cresco Labs Inc.

Equities

CL

CA22587M1068

Pharmaceuticals

Cresco Labs Inc. Provides Earnings Guidance for the Year 2021

Latest news about Cresco Labs Inc.

Chart Cresco Labs Inc.

Company Profile

Income Statement Evolution

Ratings for Cresco Labs Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals